| Last Price | Today's Change | 52-Week Range | Trading Volume |
|---|---|---|---|
| 5.28 | 0.05 (+0.96%) | 4.20 - 8.53 | 24.7 thousand (Below Avg) |
Market data as of 3:59PM 05/24/13. Quotes are delayed by at least 15 min.
| Open | 5.06 |
|---|---|
| Previous Close | 5.23 |
| Day's Range | 5.06 - 5.30 |
| Market Cap | 179.2M |
| Avg Volume (10 Day) | 42.4K |
| Price/Earnings (Trailing 12 Mo.) | -- |
| Earnings Per Share (Trailing 12 Mo.) | -0.2 |
| Dividend Yield | No Dividend |


These seven metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Performed well consistently? | Fail |
|---|---|
| Avoids excess debt? | Fail |
| Converting sales to profits? | Fail |
| Shareholder's money handled rationally? | Neutral |
| Increased shareholder value? | Neutral |
| Consistently increased owner earnings? | Fail |
| Sells at 25% discount to intrinsic value? | Fail |


These eight metrics are a snap to calculate, thanks to Quicken.com's One-Click Scorecard. Our goal with this tool is to help you evaluate potential investment candidates and eliminate those equities that aren't up to snuff. One-Click Scorecard won't do all the homework necessary for you to reach a decision, but it will help you develop a list of quality stocks to watch and study further.
| Pays a cash dividend? | Fail |
|---|---|
| Room to increase dividends? | Fail |
| Increased earnings over time? | Fail |
| Borrows within reasonable limits? | Neutral |
| Stock is undervalued? | Fail |
| Have investors caught on? | Fail |
| Has support of institutional investors? | Fail |
| Has sufficient liquidity? | Pass |
No news headlines available for NYMX
| NYMX | Industry Range | |
|---|---|---|
| Revenue Growth (1yr) | 2.70% | |
| Net Income Growth (1yr) | -- | |
| Total Debt/Equity | -- | |
| LT Debt/Equity | -- | |
| Earnings Yield | -- | |
| Price/Sales | 56.51 |
| Company | Last | Change |
|---|---|---|
| Atossa Genetics Inc | 5.13 | 0.00% |
| Tekmira Pharmaceuticals Corp | 4.71 | -0.80% |
| Vermillion Inc | 3.08 | 0.00% |
| Chembio Diagnostics Inc | 4.50 | 0.00% |
| Rosetta Genomics Ltd | 4.01 | +0.50% |
Data is delayed by at least 15 min.